Objectives: Minimally invasive extracorporeal CO 2 removal is an accepted supportive treatment in chronic obstructive pulmonary disease patients. Conversely, the potential of such technique in treating acute respiratory distress syndrome patients remains to be investigated. The aim of this study was: 1) to quantify membrane lung CO 2 removal (Vco 2ML ) under different conditions and 2) to quantify the natural lung CO 2 removal (Vco 2NL ) and to what extent mechanical ventilation can be reduced while maintaining total expired CO 2 (Vco 2tot = Vco 2ML + Vco 2NL ) and arterial Pco 2 constant. Design: Experimental animal study. Setting:
I n 1977, we described extracorporeal CO 2 removal (ECCO 2 R) as a tool for attenuating high pressure/high volume mechanical ventilation in low compliance respiratory systems (1) (2) (3) (4) (5) (6) (7) . In the wake of the influenza H1N1 epidemic (8) and the Conventional ventilatory support vs extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR) trial (9) , venovenous extracorporeal lung support has acquired an important role in the treatment of severe respiratory failure.
The extracorporeal support includes both supplying oxygen (extracorporeal membrane oxygenation [ECMO] ) and removing CO 2 from the venous blood (ECCO 2 R). In the absence of an artificial lung, expired CO 2 (Vco 2 ) and oxygen consumption (Vo 2 ) are strictly related according to the metabolic respiratory quotient (R = Vco 2 /Vo 2 ). At equilibrium, this ratio can vary between 0.7 and 1. The addition of an artificial lung enables a dissociation of oxygenation from CO 2 removal. Indeed, as an example, most of the CO 2 can be removed by an artificial lung while most of the oxygen is delivered through the natural lung. The opposite is also true, depending on the extracorporeal blood and gas flows settings and on the mechanical ventilation setting (for details, see supplemental materials, Supplemental Digital Content 1, http://links.lww.com/CCM/E33). A recent position paper referred to ECMO as a technique for providing oxygenation and CO 2 removal at high blood flow, and to ECCO 2 R as a technique for removing CO 2 at low extracorporeal blood flow (ECBF) (10) .
CO 2 removal depends on several factors, that is, the artificial lung surface area and its specific features, the Pco 2 of the venous blood entering the artificial lung, and the extracorporeal flows of blood and gas. At equilibrium, that is, at a constant arterial Pco 2 , membrane lung CO 2 removal (Vco 2ML ) plus the natural lung CO 2 removal (Vco 2NL ) equals the CO 2 produced by the metabolism (Vco 2tot = Vco 2ML + Vco 2NL ). Therefore, increasing Vco 2ML allows a corresponding decrease in alveolar ventilation by an extent that depends on the Vco 2ML /Vco 2tot ratio. The rational use of ECCO 2 R to allow adjustments of the mechanical ventilation requires knowledge of both the Vco 2ML and the Vco 2NL . Unfortunately, most of the available ECCO 2 R or ECMO devices have no provisions for measuring either Vco 2ML or Vco 2NL . In this study, we tested a minimally invasive ECCO 2 R device, the ProLung system (Estor, Pero, Milan, Italy). The goal was to 1) define the Vco 2ML under different conditions of extracorporeal blood and gas flows, membrane surface, and inflow Pco 2 and 2) measure to what extent we were able to decrease Vco 2NL and mechanical ventilation, whereas maintaining a constant arterial Pco 2 under each condition. All this would clarify whether the minimally invasive ECCO 2 R would provide the physiologic prerequisites for being considered for use even in severe adult respiratory distress syndrome (ARDS).
MATERIALS AND METHODS
The experiments were performed after ethical committee approval in eight female domestic pigs (57.7 ± 5 kg) under general anesthesia in the supine position. The animals were instrumented with an endotracheal tube, esophageal balloon, and central venous, pulmonary artery, femoral artery, and urinary catheters. An electrolyte solution (Sterofundin 1/1; B. Braun Melsungen, Melsungen, Germany) was infused at 2-3 mL/kg/ hr during the entire experiment. Whenever necessary, colloids (Gelafundin 4%) and norepinephrine were administered in order to maintain the mean arterial pressure above 60 mm Hg. For details, see supplementary materials (Supplemental Digital Content 1, http://links.lww.com/CCM/E33).
Extracorporeal Setting and Measurements
A 13F double lumen catheter (Joline; JOLINE GmbH & Co. KG, Hechingen, Germany) was inserted into a femoral vein, and ECCO 2 R was performed with the ProLung System (Estor, Pero, Milan, Italy). This device consisted of a hemoperfusion cartridge (ProLUNG, surface area 1.8 m 2 , polymethylpentene membrane, filling volume 125 mL; Euroset, Medolla, Modena, Italy), a roller pump (ESTORflow; Medica, Medolla, Modena, Italy), and its circuit. Anticoagulation was provided by the continuous infusion of unfractionated heparin to maintain the activated clotting time at about 300 seconds. This target was chosen to avoid possible thrombotic events during the experiments as porcine blood coagulates more readily than that of humans (11, 12) . Vco 2ML was measured through a side-stream device (ProLung Meter; Estor, Pero, Milan, Italy). Animals were ventilated with an Avea ventilator (Vyaire Medical, Mettawa, IL), and Vco 2NL was measured by the Di-CO2R system (DIMAR, Medolla, Modena, Italy). Vco 2tot was the sum of Vco 2NL plus Vco 2ML . The natural and membrane lung Vo 2 (Vo 2NL •Vo 2ML ) were computed with the Fick equation.
Experimental Design
The experimental animals underwent ECCO 2 R at three set levels of Paco 2 (30, 55 , and 80 mm Hg), four ECBF rates (100, 200, 300, and 400 mL/min), and three gas flow rates (4, 6, and 12 L/min/1.8 m 2 ). In seven pigs, we tested two artificial lungs in parallel. In each combination of extracorporeal gas and blood flow, artificial lung surface, and Paco 2 , we aimed at maintaining Vco 2tot constant by compensating any change in Vco 2ML with an appropriate change in Vco 2NL by modifying minute ventilation. Measurements were taken 15 minutes after the set Paco 2 was reached (Fig. S1 , Supplemental Digital Content 1, http://links. lww.com/CCM/E33). The time to reach the set Paco 2 averaged 34.9 ± 24.9 minutes.
Outcome Measures
At each ECCO 2 R step, we measured the following variables: "Gas exchange": arterial, central venous and mixed venous blood gases, end-tidal CO 2 , dead space, shunt fraction, Vco 2NL , and Vo 2NL ; "Hemodynamics": arterial, central venous and pulmonary pressures, cardiac output, and urine output; "Lung mechanics": functional residual capacity (only at baseline), minute volume and alveolar ventilation, airways peak pressure, airways and esophageal plateau, and end-expiratory pressures (PEEP) pressures, mechanical power (13), transpulmonary pressure, driving pressure, chest wall, lung and respiratory system elastances; "Extracorporeal variables": extracorporeal blood and gas flow, inflow and outflow pressures, inflow and outflow blood gases,Vco 2ML , and Vo 2ML .
Statistical Analysis
Data are reported as means and sds. In the figures, we used the se for sake of clarity. The Vco 2tot and the Vco 2ML /Vco 2tot were also grouped in tertiles. We used the analysis of variance test with Tukey adjustment to compare groups. Student t test was used when appropriate. A p value of less than 0.05 was considered statistically significant. Linear regression was used to assess the association between Vco 2ML and inflow Pco 2 , blood flow and gas flow. Statistical analysis was performed using R software (The R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
The measured values of arterial Pco 2 for the targeted values of 30, 55, and 80 mm Hg were 30.9 ± 2.6, 55 ± 4.8, and 81.3 ± 9.3 mm Hg, respectively, corresponding to inflow Pco 2 values in the artificial lung of 38.9 ± 3.3, 65 ± 5.7, and 89.9 ± 12.9 mm Hg, respectively.
In Figure 1 , we show Vco 2ML as a function of inflow Pco 2 at ECBF rates ranging from 100 to 400 mL/min (Fig. 1A) . In Figure 1B , we show Vco 2ML as a function of ECBF at the set Pco 2 values of 30, 55, and 80 mm Hg. As shown, in this minimally invasive ECCO 2 R, Vco 2ML increased linearly both with inflow Pco 2 and ECBF, ranging from a minimum of 12.4 mL/ min up to 171 mL/min. Vco 2ML did not change when gas flow was increased from 4 to 6 and 12 L/min (p = 0.59) ( In Figure 3A , we show Vco 2ML /Vco 2tot as a function of Vco 2tot (artificial + natural lung). For sake of clarity, in Figure 3B , Vco 2ML /Vco 2tot is plotted as a function of quintiles of Vco 2tot . As shown, Vco 2ML /Vco 2tot was a function Vco 2tot, and it was highly variable. In Figure 4 , we show minute ventilation as a function of Vco 2ML /Vco 2tot . As shown, to maintain the targeted arterial Pco 2 , minute ventilation was reduced in a manner proportional to Vco 2ML /Vco 2tot . For a given ECBF rate, the latter, in turn, depended on the degree of hypercapnia. As an example, in these healthy animals, the minute ventilation of 12 L/min applied to maintain the set Pco 2 of 30.9 ± 2.6 mm Hg could be reduced up to 1.51 L/min or even below 1L/min if one was willing to accept an increase in Pco 2 levels to 55 or 80 mm Hg, respectively.
In Table 1 , we grouped the Vco 2ML /Vco 2tot in tertiles defined as low (up to 26.6%) moderate (up to 50.2%), and high (up to 98.9%), and we show its association with metabolic, gas exchange, hemodynamics, and respiratory variables. Arterial and venous oxygenation were kept constant by a mild increase in PEEP to keep the mean airway pressure constant when minute ventilation was decreased, and by an increase in Fio 2 , to keep alveolar Po 2 constant when the respiratory quotient of the natural lung was decreased (14) . The hemodynamic variables remained within a normal range despite a significant decrease in cardiac output, primarily due to a decreased heart rate. No signs of tissues hypoxia were noted. The extent of the Vco 2ML / Vco 2tot ratio allowed a marked change in the respiratory variables. Indeed, we were able to reduce minute ventilation from a baseline value of 7.4 L/min to 1.9 L/min, and the mechanical power, a comprehensive variable of ventilator-induced lung injury determinants, from 9.3 to 2.6 J/min. 
DISCUSSION
The main result of this study was that a considerable amount of CO 2 was removed by the Estor ProLung system using only a minimally invasive cannulation and a blood flow rate similar to that used in renal dialysis. Accepting a Paco 2 of 74 mm Hg and pH 7.3, we were able to remove up to 138.8 mL/min of CO 2 . This allowed us to reduce total ventilation from 7.4 to 1.9 L/min with a corresponding reduction in mechanical power from 9.3 to 2.6 J/min with no detectable drawbacks ( Table 1) . Vco 2ML depends on several factors, namely inflow Pco 2 , extracorporeal blood and gas flows, and membrane lung characteristics, that is, gas diffusion coefficient and surface area (3). Typically, during high-flow venovenous extracorporeal support, Vco 2ML increases linearly with gas flow and logarithmically with blood flow for a given inflow Pco 2 (3) . Yet in our study on lowflow venovenous ECCO 2 R, the Vco 2ML was independent from gas flow, whereas it increased linearly with ECBF. In our experimental setting, inflow Pco 2 and ECBF were the primary determinants of Vco 2ML , which was not affected by increasing gas flow above 4 L/min. Of note, however, the artificial gas/blood flows ratios we implemented were always remarkably elevated, ranging from a minimum of 30 to a maximum of 40. This suggests that, as far as the gas flow is concerned, Vco 2ML was already maximal with the single 1.8 m 2 lung, as indicated by similar outflow Pco 2 levels, regardless of inflow Pco 2 or blood flow (Fig. 2) . Therefore, within the range of our study variables (blood flow rate 100-400 mL/min and inflow Pco 2 30-80 mm Hg), outflow Pco 2 was close to its asymptote. However, doubling the lung surface increased Vco 2ML by about 14%. This was likely due to a 100 % increase in transit time which gave a small but significant decrease in outflow Pco 2 from 10 to 7 mm Hg.
In these experiments, we used animals weighing 57 kg to simulate small adult humans. The degree of adjustment of mechanical ventilation depends on the Vco ML /Vco 2tot ratio attained. TheVco 2ML is a function of inflow Pco 2 and ECBF, whereas the Vco 2tot (Vco 2ML + Vco 2NL ) depends also on the ventilator settings and the metabolic CO 2 production. In our experiments, during the CO 2 removal, the metabolic activity remained constant (Table 1) Indeed, the appropriate combination of ECBF and hypercapnia, the determinants of Vco 2ML , made possible that in some animals the artificial lung removed nearly 100% of the Vco 2tot (Fig. 3) . It is worth remembering that, the removal of 50% of the Vco 2tot by the membrane lung, which can be achieved with the device used in this study, allows a reduction of total ventilation by up to 70%. Obviously, the mechanical power acting on the lung, which includes all the components of possibly injurious mechanical ventilation, can be reduced by the same fraction. The extent at which the mechanical ventilation may be reduced, may be estimated by using the equation 1 which gives a first approximation of the Vco ML that may be reached by applying the minimally invasive technique.
Our results compare favorably with those of previous studies, conducted with similar blood flow rates and catheter sizes. Indeed, using an artificial lung with a surface area of 0.32 m 2 , Godet et al (15) reported a Vco 2ML between 35 and 75 mL/min, whereas Livigni et al (16) who did not measure the Vco 2ML , described a Paco 2 reduction of 20% from baseline (17) . In another experimental setup using an artificial lung with a surface of 0.67 m 2 , Turani et al (18) measured a Vco 2ML of 37-56 mL/min, whereas Grasso et al (17) reported a Vco 2ML /Vco 2tot of approximately 40% with a reduction in minute ventilation of about 50%. These values are lower than those observed in our experiments, where the maximum Vco 2ML was 171 mL/min, and Vco 2ML /Vco 2tot approached 1.0 in some cases (Figs. 3 and 4) . Zanella et al (19) using a blood flow of 250 mL/min, a membrane lung surface of 1.8 m 2 , an inflow Pco 2 of 60.9 mm Hg, associated with a dialyser and a ventilation of acidified dialysate, reported a Vco 2ML of 86 mL/min compared with the 69.4 mL/min we computed using equation 1 with the same input conditions. The volume of CO 2 eliminated through the artificial lung in our study was probably larger than most of the volumes reported previously (15) (16) (17) (18) due to the larger surface area of the membrane lung. Although polymethylpentene membrane lungs are associated with a lower consumption of clotting factors (20) , there may still be a slight risk of stasis and clotting with the low flow rate over a large membrane surface area. In these short-term experiments with the targeted activated clotting time of 300 seconds, we observed neither clotting in the system nor any decrease in its performance, nor any hemorrhagic complications. However, these results can obviously not be directly translated to the clinical setting.
The present indications for ECCO 2 R with ECBFs of less than 0.5 L/min, as recently reviewed by Camporota et al (21) refer mainly to the treatment of uncontrolled hypercapnia in chronic obstructive pulmonary disease, where this technique is largely accepted, whereas there are few studies on its use as a bridge to lung transplant and as a support in thoracic surgery. However, there is still no indication for its use in severe ARDS, primarily because this minimally invasive technique cannot correct the hypoxemia, which is the major concern in these patients (22, 23) . Indeed, high-flow ECMO can provide up to 100% of the oxygen demand, whereas ECCO 2 R can only provide, at most, ca. 10 mL/min of oxygen. It must be underlined, however, that ECCO 2 R can be employed to reduce the invasiveness of ventilation and, thereby, the risk of ventilator-induced lung injury, as shown by Terragni et al (24) .
Therefore, it is very low oxygen delivery capacity is the main conceptual obstacle to using this minimally invasive technique even in severe ARDS. However, one may question whether introducing a large amount of oxygen into the venous blood is the most rational way to treat these patients, and one may critically examine what happens during high-flow ECMO, for which the hypoxemia is the primary indication (23) . The introduction of a large amount of oxygen during venovenous ECMO induces a sharp increase in mixed venous oxygen saturation and oxygen tension, which in turn has two effects, that is, a decrease in oxygen transfer throughout the natural lung, and the loss of hypoxic pulmonary vasoconstriction (25) (26) (27) , which is still functional in ARDS (28) . As a consequence, the increase in arterial oxygenation is due solely to the increased oxygen tension in the venous blood shunting throughout the natural lung. These mechanisms account for the modest increase in Pao 2 that one observes immediately after high-flow ECMO is instituted: the oxygenation of venous blood is increased, but the loss of pulmonary vasoconstriction leads to a marked increase in right-to-left shunt. Therefore, the possible subsequent increase in Pao 2 is not necessarily due to the direct effects of ECMO on oxygenation but to an improvement in physiopathology due to the changes in the ventilatory conditions that ECMO makes possible (29) . However, the same changes in the ventilatory settings are possible due to the removal of CO 2 instead of the addition of oxygen to the venous blood. Therefore, we may speculate that it is possible to consider the use of ECCO 2 R even in severe ARDS. Indeed, first of all, this technique allows one to reduce the invasiveness of mechanical ventilation to the levels used during high-flow ECMO (30) . Second, oxygenation is maintained via the natural lung as long as mean airway pressure is maintained when mechanical ventilation variables are reduced, for example, by increasing PEEP. Third, hypoxic vasoconstriction remains unaltered without any increase in right-to-left shunt and, finally, the advantages of this minimally invasive approach consist in its being easy to implement (double lumen 13F single cannula), easy to monitor and likely requiring an anticoagulation similar to that used in hemodialysis, including the possibility of regional anticoagulation (31, 32) .
